We just ran across an interesting article that spotlights four key takeaways from the Asembia Specialty Pharmacy Summit held earlier this year.
Well, the article is from the perspective of four lawyers who attended the Summit.
Hmmmmm!!!
Their perspectives and conclusions bear merit for all specialty pharmacies to factor into their strategic planning as they are perhaps better positioned to look at the forest as well as all them there trees.
Here’s a snapshot of their observations……
- Infusion Continues to Dominate Conversations on Market Activity — infusion will continue to impact the overall market especially influenced by site-of-service.
- IRA Implementation Continues to Raise Questions about Impact on the Specialty Pharmacy Market — at this point it remains unclear as to the impact on specialty pharmacies but it is clear that the Act will begin to shift the reimbursement biosphere.
- Outside of True “Specialty,” Cash is King — manufacturers are focusing on cash-pay programs and pharma service vendors are well poised to provide robust support for these programs. But, further attempts by manufacturers to establish closer relationships with patients and eliminate costly channel participants like wholesalers and commercial pharmacies will proliferate.
- 340B Continues to Come Up, Particularly in Distribution and Infusion Conversations — drug manufacturer contract pharmacy restrictions will lead to new and “innovative” models popping up.
——————————————————————————————–
Key Takeaways from 2024 Asembia Specialty Pharmacy Summit
CLICK HERE to read the full article and the authors’ conclusions.
